Skip to content

Winning the War on Cancer

Creating the next-generation of iPSC-derived natural killer and macrophage cell therapies

We Are Pushing the Boundaries of Science to the Edge of What’s Possible

We are passionate about delivering novel therapies to patients in need by harnessing our cutting-edge approach in cellular immunotherapy. We are building a pipeline of iPSC-derived natural killer cell (iNK) and macrophage (iMACs) cellular immunotherapy candidates derived from our deep expertise in iPSC differentiation, genetic engineering and immune cell biology.

We are developing the next generation of cellular immunotherapies designed to bring safe, effective and affordable treatments to patients in need through our intelligently engineered, homogenous and scalable off-the-shelf products enabled by our iNK and iMACs cellular immunotherapy platforms.

In the News